Biologics by McKesson Selected as Limited Distribution Specialty Pharmacy Provider for HERNEXEOS® (zongertinib tablets)
Effective July 13, Boehringer Ingelheim’s HERNEXEOS® (zongertinib tablets) will be supported by Biologics by McKesson as a limited distribution specialty pharmacy partner.
Biologics by McKesson Selected as Limited Distribution Specialty Pharmacy Provider for PHYRAGO™
Effective July 7, Cycle Pharmaceuticals’ PHYRAGO™ (dasatinib) will be supported by Biologics by McKesson as a limited distribution specialty pharmacy partner
DECNUPAZ™(pivekimab sunirine-pvzy), FDA‑Approved for Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN), Exclusively Available at Biologics by McKesson
Biologics by McKesson became the exclusive specialty pharmacy provider for DECNUPAZ, an intravenous therapy approved for patients with blastic plasmacytoid dendritic cell neoplasm.
ZYCUBO® (copper histidinate), First FDA-Approved Treatment for Patients with Menkes Disease, Exclusively Available at Biologics by McKesson in the United States
Biologics by McKesson became the exclusive specialty pharmacy provider for ZYCUBO, the first FDA-approved treatment for pediatric patients with Menkes disease.
Biologics by McKesson’s Pharmacy Elite™ Selected as Hub for Rigel Pharmaceuticals’ Tavalisse®, Gavreto® and Rezlidhia®
Biologics by McKesson’s Pharmacy Elite was selected as Rigel’s hub for Tavalisse, Gavreto, and Rezlidhia, supporting access services including benefits investigation, prior authorization, and financial assistance navigation.
AQVESME® (mitapivat), FDA-Approved for Adults with Thalassemia, Exclusively Available at Biologics by McKesson
Biologics by McKesson became the sole specialty pharmacy provider for AQVESME, indicated for adults with non-transfusion-dependent or transfusion-dependent alpha- or beta-thalassemia.
KOMZIFTI® (ziftomenib), FDA-Approved for Treatment of Adults with Relapsed or Refractory NPM1-Mutated Acute Myeloid Leukemia, Available at Biologics by McKesson
Biologics by McKesson was selected as a limited specialty pharmacy provider for Komzifti, an oral menin inhibitor for adults with relapsed or refractory NPM1-mutated acute myeloid leukemia.
INLURIYO™ (imlunestrant) FDA-Approved for Treatment of ER+, HER2-, ESR1-Mutated Advanced or Metastatic Breast Cancer, Available at Biologics by McKesson
Biologics by McKesson was selected as a limited specialty pharmacy provider for Inluriyo, an oral estrogen receptor antagonist for ESR1-mutated, ER-positive, HER2-negative advanced or metastatic breast cancer.
PALSONIFY™ (paltusotine), FDA-Approved for Treatment of Adults with Acromegaly Who Had an Inadequate Response to Surgery and/or for Whom Surgery Is Not an Option, Available at Biologics by McKesson
Biologics by McKesson was selected as a limited specialty pharmacy provider for PALSONIFY, the first once-daily oral therapy for adults with acromegaly who need an alternative to surgery.
Precigen Selects McKesson to Support Specialty Pharmacy and Patient Hub Services for Launch of Novel Immunotherapy
Biologics by McKesson, in partnership with InspiroGene by McKesson, was chosen as the exclusive specialty pharmacy for a newly approved immunotherapy for adults with recurrent respiratory papillomatosis.